{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:45:42Z","timestamp":1792197942349,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372841"],"award-info":[{"award-number":["82372841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172975"],"award-info":[{"award-number":["82172975"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972438"],"award-info":[{"award-number":["81972438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272992"],"award-info":[{"award-number":["82272992"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91954106"],"award-info":[{"award-number":["91954106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872109"],"award-info":[{"award-number":["81872109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metabolic reprogramming is crucial in developing endometrial cancer (EC); however, the mechanisms through which tumor suppressors control metabolites that drive cell proliferation and tumor growth remain unclear. ARID1A, an SWI\/SNF chromatin remodeling complex subunit, is frequently mutated in endometrium-related malignancies. Here, EC tumors with ARID1A deleted exhibit increased polyamine production, which enhances malignant proliferative capacity while inhibiting the efficacy of functional CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Mechanistically, ARID1A depletion in tumor cells interrupts the competitive binding of ARID1A to YAP, causing excessive YAP activation and transcriptionally increasing the expression of polyamine metabolic enzymes, thereby enhancing polyamine synthesis. Increased spermidine production from polyamines can directly hypusinate eukaryotic translation initiation factor 5A (eIF5A) at lysine residues, resulting in efficient histone demethylase LSD1 protein translation. Moreover, polyamine accumulation suppresses the recruitment of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and hampers antitumor immune responses in vivo. Notably, polyamine depletion induced by eflornithine (DFMO) significantly reduces EC cell proliferative capacity and enhances CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell efficacy. Together, these findings highlight the role of ARID1A in regulating polyamine metabolism and suggest that elevated polyamine levels in tumors enhance malignant cellular behaviors and contribute to immune evasion by inhibiting CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell-mediated cytotoxic responses. Therefore, targeting polyamine biosynthesis could be an important therapeutic strategy for ARID1A-inactivated EC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08722-0","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:16:21Z","timestamp":1775636181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ARID1A deficiency-driven reprogramming of polyamine metabolism promotes endometrial cancer malignancy and immune escape"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9131-9909","authenticated-orcid":false,"given":"Han","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9060-3881","authenticated-orcid":false,"given":"Kun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6079-631X","authenticated-orcid":false,"given":"Xiaoping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"8722_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8722_CR2","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3389\/fonc.2019.01440","volume":"9","author":"S Zhang","year":"2019","unstructured":"Zhang S, Gong TT, Liu FH, Jiang YT, Sun H, Ma XX, et al. Global, regional, and national burden of endometrial cancer, 1990-2017: results from the global burden of disease study, 2017. Front Oncol. 2019;9:1440.","journal-title":"Front Oncol"},{"key":"8722_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","volume":"161","author":"B Gu","year":"2021","unstructured":"Gu B, Shang X, Yan M, Li X, Wang W, Wang Q, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol. 2021;161:573\u201380.","journal-title":"Gynecol Oncol"},{"key":"8722_CR4","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMra1514010","volume":"383","author":"KH Lu","year":"2020","unstructured":"Lu KH, Broaddus RR. Endometrial cancer. N Engl J Med. 2020;383:2053\u201364.","journal-title":"N Engl J Med"},{"key":"8722_CR5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399:1412\u201328.","journal-title":"Lancet"},{"key":"8722_CR6","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"8722_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","volume":"31","author":"AD Cherniack","year":"2017","unstructured":"Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer cell. 2017;31:411\u201323.","journal-title":"Cancer cell"},{"key":"8722_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67\u201373.","journal-title":"Nature"},{"key":"8722_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer cell. 2012;21:297\u2013308.","journal-title":"Cancer cell"},{"key":"8722_CR10","doi-asserted-by":"crossref","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368:eaaw5473.","DOI":"10.1126\/science.aaw5473"},{"key":"8722_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"8722_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200.","journal-title":"Sci Adv"},{"key":"8722_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102287","volume":"100","author":"J Mullen","year":"2021","unstructured":"Mullen J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287.","journal-title":"Cancer Treat Rev"},{"key":"8722_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500447","volume":"1","author":"C Kadoch","year":"2015","unstructured":"Kadoch C, Crabtree GR. Mammalian SWI\/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci Adv. 2015;1:e1500447.","journal-title":"Sci Adv"},{"key":"8722_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/PAS.0b013e318212782a","volume":"35","author":"B Guan","year":"2011","unstructured":"Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35:625\u201332.","journal-title":"Am J Surg Pathol"},{"key":"8722_CR16","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.1158\/0008-5472.CAN-11-1562","volume":"71","author":"B Guan","year":"2011","unstructured":"Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI\/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71:6718\u201327.","journal-title":"Cancer Res"},{"key":"8722_CR17","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532\u201343.","journal-title":"N Engl J Med"},{"key":"8722_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1006\/bbrc.2000.2601","volume":"271","author":"K Igarashi","year":"2000","unstructured":"Igarashi K, Kashiwagi K. Polyamines: mysterious modulators of cellular functions. Biochem Biophys Res Commun. 2000;271:559\u201364.","journal-title":"Biochem Biophys Res Commun"},{"key":"8722_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/iub.230","volume":"61","author":"AE Pegg","year":"2009","unstructured":"Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61:880\u201394.","journal-title":"IUBMB Life"},{"key":"8722_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aar2606","volume":"4","author":"A Arruabarrena-Aristorena","year":"2018","unstructured":"Arruabarrena-Aristorena A, Zabala-Letona A, Carracedo A. Oil for the cancer engine: the cross-talk between oncogenic signaling and polyamine metabolism. Sci Adv. 2018;4:eaar2606.","journal-title":"Sci Adv"},{"key":"8722_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.molcel.2019.08.005","volume":"76","author":"H Zhang","year":"2019","unstructured":"Zhang H, Alsaleh G, Feltham J, Sun Y, Napolitano G, Riffelmacher T, et al. Polyamines control eIF5A hypusination, TFEB translation, and autophagy to reverse B cell senescence. Mol Cell. 2019;76:110\u2013125 e119.","journal-title":"Mol Cell"},{"key":"8722_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41568-022-00473-2","volume":"22","author":"CE Holbert","year":"2022","unstructured":"Holbert CE, Cullen MT, Casero RA Jr, Stewart TM. Polyamines in cancer: integrating organismal metabolism and antitumour immunity. Nat Rev Cancer. 2022;22:467\u201380.","journal-title":"Nat Rev Cancer"},{"key":"8722_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41568-018-0050-3","volume":"18","author":"RA Casero Jr","year":"2018","unstructured":"Casero RA Jr, Murray Stewart T, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer. 2018;18:681\u201395.","journal-title":"Nat Rev Cancer"},{"key":"8722_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nrc1454","volume":"4","author":"EW Gerner","year":"2004","unstructured":"Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004;4:781\u201392.","journal-title":"Nat Rev Cancer"},{"key":"8722_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41392-020-0170-6","volume":"5","author":"X Wen","year":"2020","unstructured":"Wen X, Wan J, He Q, Wang M, Li S, Jiang M, et al. p190A inactivating mutations cause aberrant RhoA activation and promote malignant transformation via the Hippo-YAP pathway in endometrial cancer. Signal Transduct Target Ther. 2020;5:81.","journal-title":"Signal Transduct Target Ther"},{"key":"8722_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41388-022-02550-0","volume":"42","author":"M Wang","year":"2023","unstructured":"Wang M, Yan Q, Song Y, Zhang Z, Chen X, Gao K, et al. Loss-of-function mutations of SOX17 lead to YAP\/TEAD activation-dependent malignant transformation in endometrial cancer. Oncogene. 2023;42:322\u201334.","journal-title":"Oncogene"},{"key":"8722_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-018-0658-1","volume":"563","author":"L Chang","year":"2018","unstructured":"Chang L, Azzolin L, Di Biagio D, Zanconato F, Battilana G, Lucon Xiccato R, et al. The SWI\/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 2018;563:265\u20139.","journal-title":"Nature"},{"key":"8722_CR28","doi-asserted-by":"publisher","first-page":"7819","DOI":"10.1073\/pnas.92.17.7819","volume":"92","author":"HI Chen","year":"1995","unstructured":"Chen HI, Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA. 1995;92:7819\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8722_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41568-023-00579-1","volume":"23","author":"JM Franklin","year":"2023","unstructured":"Franklin JM, Wu Z, Guan KL. Insights into recent findings and clinical application of YAP and TAZ in cancer. Nat Rev Cancer. 2023;23:512\u201325.","journal-title":"Nat Rev Cancer"},{"key":"8722_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41556-022-00848-5","volume":"24","author":"H Li","year":"2022","unstructured":"Li H, Wu BK, Kanchwala M, Cai J, Wang L, Xing C, et al. YAP\/TAZ drives cell proliferation and tumour growth via a polyamine-eIF5A hypusination-LSD1 axis. Nat Cell Biol. 2022;24:373\u201383.","journal-title":"Nat Cell Biol"},{"key":"8722_CR31","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","volume":"26","author":"Y Liu-Chittenden","year":"2012","unstructured":"Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26:1300\u20135.","journal-title":"Genes Dev"},{"key":"8722_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000445640","volume":"39","author":"W Pan","year":"2016","unstructured":"Pan W, Wang Q, Zhang Y, Zhang N, Qin J, Li W, et al. Verteporfin can reverse the paclitaxel resistance induced by YAP over-expression in HCT-8\/T cells without photoactivation through inhibiting YAP expression. Cell Physiol Biochem. 2016;39:481\u201390.","journal-title":"Cell Physiol Biochem"},{"key":"8722_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32788-x","volume":"13","author":"J Zhou","year":"2022","unstructured":"Zhou J, Pang J, Tripathi M, Ho JP, Widjaja AA, Shekeran SG, et al. Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression. Nat Commun. 2022;13:5202.","journal-title":"Nat Commun"},{"key":"8722_CR34","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1073\/pnas.78.5.2869","volume":"78","author":"MH Park","year":"1981","unstructured":"Park MH, Cooper HL, Folk JE. Identification of hypusine, an unusual amino acid, in a protein from human lymphocytes and of spermidine as its biosynthetic precursor. Proc Natl Acad Sci USA. 1981;78:2869\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8722_CR35","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.1093\/nar\/gkx532","volume":"45","author":"BS Shin","year":"2017","unstructured":"Shin BS, Katoh T, Gutierrez E, Kim JR, Suga H, Dever TE. Amino acid substrates impose polyamine, eIF5A, or hypusine requirement for peptide synthesis. Nucleic Acids Res. 2017;45:8392\u2013402.","journal-title":"Nucleic Acids Res"},{"key":"8722_CR36","doi-asserted-by":"publisher","first-page":"7326","DOI":"10.1093\/nar\/gkx479","volume":"45","author":"V Pelechano","year":"2017","unstructured":"Pelechano V, Alepuz P. eIF5A facilitates translation termination globally and promotes the elongation of many non polyproline-specific tripeptide sequences. Nucleic Acids Res. 2017;45:7326\u201338.","journal-title":"Nucleic Acids Res"},{"key":"8722_CR37","doi-asserted-by":"publisher","first-page":"18710","DOI":"10.1074\/jbc.TM118.003341","volume":"293","author":"MH Park","year":"2018","unstructured":"Park MH, Wolff EC. Hypusine, a polyamine-derived amino acid critical for eukaryotic translation. J Biol Chem. 2018;293:18710\u20138.","journal-title":"J Biol Chem"},{"key":"8722_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molcel.2013.04.021","volume":"51","author":"E Gutierrez","year":"2013","unstructured":"Gutierrez E, Shin BS, Woolstenhulme CJ, Kim JR, Saini P, Buskirk AR, et al. eIF5A promotes translation of polyproline motifs. Mol Cell. 2013;51:35\u201345.","journal-title":"Mol Cell"},{"key":"8722_CR39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature08034","volume":"459","author":"P Saini","year":"2009","unstructured":"Saini P, Eyler DE, Green R, Dever TE. Hypusine-containing protein eIF5A promotes translation elongation. Nature. 2009;459:118\u201321.","journal-title":"Nature"},{"key":"8722_CR40","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1021\/acs.jmedchem.0c02176","volume":"64","author":"XJ Dai","year":"2021","unstructured":"Dai XJ, Liu Y, Xue LP, Xiong XP, Zhou Y, Zheng YC, et al. Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1. J Med Chem. 2021;64:2466\u201388.","journal-title":"J Med Chem"},{"key":"8722_CR41","doi-asserted-by":"publisher","first-page":"e0235705","DOI":"10.1371\/journal.pone.0235705","volume":"15","author":"R Soldi","year":"2020","unstructured":"Soldi R, Ghosh Halder T, Weston A, Thode T, Drenner K, Lewis R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch\/Sucrose-NonFermentable (SWI\/SNF) complex mutated ovarian cancer. PloS one. 2020;15:e0235705.","journal-title":"PloS one"},{"key":"8722_CR42","first-page":"811","volume":"23","author":"Z Wang","year":"2021","unstructured":"Wang Z. Polyamines instruct T-cell differentiation. Nat Cell Biol. 2021;23:811.","journal-title":"Nat Cell Biol"},{"key":"8722_CR43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","volume":"30","author":"J Kim","year":"2019","unstructured":"Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 2019;30:434\u201346.","journal-title":"Cell Metab"},{"key":"8722_CR44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Martinez-Reyes","year":"2021","unstructured":"Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669\u201380.","journal-title":"Nat Rev Cancer"},{"key":"8722_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pharmthera.2018.05.001","volume":"190","author":"R Mathur","year":"2018","unstructured":"Mathur R. ARID1A loss in cancer: towards a mechanistic understanding. Pharm Ther. 2018;190:15\u201323.","journal-title":"Pharm Ther"},{"key":"8722_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s43018-020-00160-x","volume":"2","author":"S Wu","year":"2021","unstructured":"Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat Cancer. 2021;2:189\u2013200.","journal-title":"Nat Cancer"},{"key":"8722_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","volume":"35","author":"H Ogiwara","year":"2019","unstructured":"Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer cell. 2019;35:177\u2013190 e178.","journal-title":"Cancer cell"},{"key":"8722_CR48","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ccell.2023.03.002","volume":"41","author":"W Zhou","year":"2023","unstructured":"Zhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer cell. 2023;41:740\u2013756 e710.","journal-title":"Cancer cell"},{"key":"8722_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.tem.2018.04.006","volume":"29","author":"A Ardestani","year":"2018","unstructured":"Ardestani A, Lupse B, Maedler K. Hippo signaling: key emerging pathway in cellular and whole-body metabolism. Trends Endocrinol Metab. 2018;29:492\u2013509.","journal-title":"Trends Endocrinol Metab"},{"key":"8722_CR50","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.cmet.2018.07.010","volume":"28","author":"JH Koo","year":"2018","unstructured":"Koo JH, Guan KL. Interplay between YAP\/TAZ and metabolism. Cell Metab. 2018;28:196\u2013206.","journal-title":"Cell Metab"},{"key":"8722_CR51","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00726-016-2275-3","volume":"48","author":"S Nakanishi","year":"2016","unstructured":"Nakanishi S, Cleveland JL. Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer. Amino Acids. 2016;48:2353\u201362.","journal-title":"Amino Acids"},{"key":"8722_CR52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-023-05891-2","volume":"616","author":"MS Lee","year":"2023","unstructured":"Lee MS, Dennis C, Naqvi I, Dailey L, Lorzadeh A, Ye G, et al. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Nature. 2023;616:339\u201347.","journal-title":"Nature"},{"key":"8722_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.molcel.2017.03.003","volume":"66","author":"AP Schuller","year":"2017","unstructured":"Schuller AP, Wu CC, Dever TE, Buskirk AR, Green R. eIF5A functions globally in translation elongation and termination. Mol Cell. 2017;66:194\u2013205 e195.","journal-title":"Mol Cell"},{"key":"8722_CR54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.it.2020.09.007","volume":"41","author":"E Proietti","year":"2020","unstructured":"Proietti E, Rossini S, Grohmann U, Mondanelli G. Polyamines and kynurenines at the intersection of immune modulation. Trends Immunol. 2020;41:1037\u201350.","journal-title":"Trends Immunol"},{"key":"8722_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12672-024-01034-9","volume":"15","author":"CE Holbert","year":"2024","unstructured":"Holbert CE, Casero RA Jr., Stewart TM. Polyamines: the pivotal amines in influencing the tumor microenvironment. Discov Oncol. 2024;15:173.","journal-title":"Discov Oncol"},{"key":"8722_CR56","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1073\/pnas.1219002110","volume":"110","author":"S Mandal","year":"2013","unstructured":"Mandal S, Mandal A, Johansson HE, Orjalo AV, Park MH. Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. Proc Natl Acad Sci USA. 2013;110:2169\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8722_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev.pa.35.040195.000415","volume":"35","author":"LJ Marton","year":"1995","unstructured":"Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Annu Rev Pharm Toxicol. 1995;35:55\u201391.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"8722_CR58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0021-9258(18)48472-4","volume":"267","author":"R Poulin","year":"1992","unstructured":"Poulin R, Lu L, Ackermann B, Bey P, Pegg AE. Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J Biol Chem. 1992;267:150\u20138.","journal-title":"J Biol Chem"},{"key":"8722_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/0006-291X(78)91630-3","volume":"81","author":"PS Mamont","year":"1978","unstructured":"Mamont PS, Duchesne MC, Grove J, Bey P. Anti-proliferative properties of DL-alpha-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun. 1978;81:58\u201366.","journal-title":"Biochem Biophys Res Commun"},{"key":"8722_CR60","first-page":"759","volume":"48","author":"AE Pegg","year":"1988","unstructured":"Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988;48:759\u201374.","journal-title":"Cancer Res"},{"key":"8722_CR61","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1200\/JCO.24.00546","volume":"42","author":"ES Duke","year":"2024","unstructured":"Duke ES, Bradford D, Sinha AK, Mishra-Kalyani PS, Lerro CC, Rivera D, et al. US food and drug administration approval summary: eflornithine for high-risk neuroblastoma after prior multiagent, multimodality therapy. J Clin Oncol. 2024;42:3047\u201357.","journal-title":"J Clin Oncol"},{"key":"8722_CR62","doi-asserted-by":"publisher","first-page":"e0127246","DOI":"10.1371\/journal.pone.0127246","volume":"10","author":"GL Saulnier Sholler","year":"2015","unstructured":"Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, et al. A phase I trial of DFMO targeting polyamine addiction in patients with relapsed\/refractory neuroblastoma. PloS one. 2015;10:e0127246.","journal-title":"PloS one"},{"key":"8722_CR63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","volume":"1","author":"FL Meyskens Jr","year":"2008","unstructured":"Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res. 2008;1:32\u201338.","journal-title":"Cancer Prev Res"},{"key":"8722_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105576","volume":"10","author":"SA Piha-Paul","year":"2025","unstructured":"Piha-Paul SA, Tolcher AW, Vandross AL, Spira AI, Burns MR. Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism. ESMO Open. 2025;10:105576.","journal-title":"ESMO Open"},{"key":"8722_CR65","doi-asserted-by":"crossref","unstructured":"Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, et al. STELLAR: phase III, randomized, open-label study of eflornithine plus lomustine versus lomustine alone in patients with recurrent grade 3 astrocytoma. J Clin Oncol. 2026;44:641\u201352.","DOI":"10.1200\/JCO-25-01204"},{"key":"8722_CR66","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/139087","volume":"2010","author":"TH Kim","year":"2010","unstructured":"Kim TH, Wang J, Lee KY, Franco HL, Broaddus RR, Lydon JP, et al. The synergistic effect of conditional pten loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action. J Oncol. 2010;2010:139087.","journal-title":"J Oncol"},{"key":"8722_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e04075","volume":"6","author":"AM Fedorko","year":"2020","unstructured":"Fedorko AM, Kim TH, Broaddus R, Schmandt R, Chandramouli GVR, Kim HI, et al. An immune competent orthotopic model of endometrial cancer with metastasis. Heliyon. 2020;6:e04075.","journal-title":"Heliyon"},{"key":"8722_CR68","doi-asserted-by":"crossref","unstructured":"Bowen MB, Melendez B, Zhang Q, Moreno D, Peralta L, Chan WK, et al. Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer. JCI Insight 2025;10:e185946.","DOI":"10.1172\/jci.insight.185946"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08722-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08722-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08722-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:02:59Z","timestamp":1779210179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08722-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8722"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08722-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study involved both human subjects and animal experiments, and was approved by the Ethics Review Committee of Shanghai First Maternity and Infant Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"484"}}